CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Neurogen Corporation is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Neurogen Corporation
35 Northeast Industrial Road
Phone: (203) 488-8201p:203 488-8201 Branford, CT  06405  United States Ticker: NRGN NRGN
This company was Merged or Acquired on 12/23/2009.
This company ceased filing statements with the SEC on 12/24/2009.
This company is no longer actively traded on any major stock exchange.
This is a Subsidiary, click here for the Parent Company
Business Summary
Neurogen Corporation (Neurogen) is a development company focusing on new small molecule drugs to improve the lives of patients suffering from psychiatric and neurological disorders, including Restless legs syndrome (RLS), and Parkinson’s disease. Its lead candidate is aplindore, a D2 partial agonist, for the treatment of RLS and Parkinson’s disease. As of December 31, 2008, the Company had two active programs for aplindore, which are each in Phase II clinical development. In collaboration with its partner, Merck Sharp & Dohme Limited, the Company had discovered a number of drug candidates that work as antagonists of the vanilloid receptor-1 (VR1). In December 2009, Ligand Pharmaceuticals Incorporated acquired Neurogen Corporation.

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
-Yes-Yes---

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
9/30/200912/31/2008YesYes---

Industries
SIC Code Description
2834 Pharmaceutical preparations
8731 Commercial physical and biological research
2836 Biological products, except diagnostic substances

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Chairman of the Board CraigSaxton 66 12/1/2004 1/31/2002
President, Chief Executive Officer, Director Stephen R.Davis 48 2/4/2008 1/1/1994
Senior Vice President, Chief Business and Financial Officer Thomas A.Pitler 50 4/17/2008 4/17/2008
5 additional Officers and Directors records available in full report.

General Information
Number of Employees: 6 (As of 6/30/2009)
Outstanding Shares: 69,038,691 (As of 11/4/2009)
Shareholders: 145
Stock Exchange: NASD
Federal Tax Id: 222845714
Fax Number: (203) 481-8683
Email Address: aenders@nrgn.com


Copyright © 2023 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Friday, July 21, 2023